Allport Juliette
Wolters Kluwer Health|Adis, Auckland, New Zealand.
Curr Opin Rheumatol. 2008 Jul;20(4):435-41. doi: 10.1097/BOR.0b013e3282ff0d6d.
(1) While a number of medications have been shown to induce bone loss, the actual incidence and prevalence of medication-induced osteoporosis has not been well quantified. (2) Oral corticosteroids contribute to an increased prevalence of osteoporosis and an increased incidence of fracture in a number of different populations. The increased incidence of fracture in patients receiving inhaled corticosteroids for respiratory disease may be attributed to disease pathogenesis rather than the effects of medication. (3) Other therapies that increase the incidence and/or prevalence of medication-induced osteoporosis and fracture include androgen-deprivation therapy, aromatase inhibitors, protease inhibitors, selective serotonin reuptake inhibitors and prolactin-raising antiepileptic agents. (4) It is difficult to make definitive conclusions on the actual increase in the prevalence and/or incidence of osteoporosis in patients receiving certain medications, as values are often reported differently and studies are mainly retrospective and are therefore open to inherent selection biases and other confounders. Furthermore, there is little available information as to whether specific medications within a class are associated with a higher rate of bone disease than others.
(1)虽然已有多种药物被证明会导致骨质流失,但药物性骨质疏松症的实际发病率和患病率尚未得到很好的量化。(2)口服皮质类固醇会导致多种不同人群的骨质疏松症患病率增加和骨折发生率上升。接受吸入性皮质类固醇治疗呼吸系统疾病的患者骨折发生率增加可能归因于疾病发病机制而非药物的作用。(3)其他会增加药物性骨质疏松症和骨折发生率及/或患病率的治疗方法包括雄激素剥夺疗法、芳香化酶抑制剂、蛋白酶抑制剂、选择性5-羟色胺再摄取抑制剂以及会使催乳素升高的抗癫痫药物。(4)对于接受某些药物治疗的患者骨质疏松症患病率和/或发病率的实际增加情况很难得出确切结论,因为数值报告往往不同,而且研究主要是回顾性的,因此容易存在内在的选择偏倚和其他混杂因素。此外,关于某一类药物中的特定药物是否比其他药物与更高的骨病发生率相关,几乎没有可用信息。